Federated Hermes’s Acrivon Therapeutics ACRV Stock Holding History

Federated Hermes’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11K	Buy	7,924 +2,312	+41%	+$4.03K	﹤0.01%	1834
2025 Q4	$13.5K	Buy	5,612 +3,186	+131%	+$6.93K	﹤0.01%	1810
2025 Q3	$4.39K	Buy	2,426 +108	+5%	+$152	﹤0.01%	1955
2025 Q2	$2.76K	Buy	+2,318	New	+$3.18K	﹤0.01%	1936
2024 Q1	–	Sell	-226,375	Closed	-$1.11M	–	2024
2023 Q4	$1.11M	Hold	226,375	–	–	﹤0.01%	1098
2023 Q3	$2.16M	Sell	226,375 -78,036	-26%	-$902K	0.01%	892
2023 Q2	$3.95M	Sell	304,411 -309,214	-50%	-$3.74M	0.01%	758
2023 Q1	$7.79M	Sell	613,625 -209,675	-25%	-$3.52M	0.02%	603
2022 Q4	$9.48M	Buy	+823,300	New	+$10.5M	0.03%	548

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's ACRV Position: Q1 2026 in Review

Federated Hermes increased its Acrivon Therapeutics (ACRV) stake by 41% in Q1 2026, buying an estimated $4.03K and bringing the position to 7,924 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Federated Hermes first reported a position in ACRV in Q4 2022 and has held it in 9 quarters since. The position peaked at $9.48M in Q4 2022. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Federated Hermes held 7,924 shares of Acrivon Therapeutics worth $11K as of Q1 2026.
Federated Hermes bought 2,312 Acrivon Therapeutics shares in Q1 2026, an estimated $4.03K.
Acrivon Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1834 holding.
Federated Hermes first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 9 quarters since.
Federated Hermes's Acrivon Therapeutics position peaked at $9.48M in Q4 2022.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.